DEN Networks Limited — Q2 FY26 earnings call

Call held 17 Nov 2025

Management summary

Vasa Denticity's Q2 FY26 earnings call highlighted a strategic shift towards building a robust foundation for future growth, even at the cost of short-term slower growth and margin compression. Key initiatives include expanding infrastructure, integrating the IDS Denmed acquisition, and enhancing customer experience through membership programs and revised return policies. Management expressed confidence in achieving long-term revenue and margin targets, emphasizing that current challenges are deliberate investments for sustained leadership in the Indian dental ecosystem.

Highlights

  • Strategic investments in warehouse network, inventory, and technology platform for long-term growth.

  • IDS Denmed acquisition expected to strengthen offline presence, distribution, and margin expansion.

  • Membership program successfully increased customer order frequency to 9 times/year.

  • Return-related queries reduced from 23% to 16%, with a target of below 5% within a year.

  • Broadly on track for revenue targets of ₹500-600 crore by FY27 and ₹800-1,200 crore by FY29.

Concerns

  • Slower growth observed due to deliberate internal choices and stabilization period for new investments.

  • EBITDA margin compression attributed to costs associated with new warehouses, categories, and technology upgrades.

  • Higher inventory levels, though strategic, represent a short-term inefficiency.

  • Delivery timelines remain a challenge, with an aspiration to bring average delivery time below 48 hours.

  • Transition phase for investments is expected to take longer than two quarters.

Key financials

  1. Own Brands Share of Sales 50%
  2. Return-related Queries (Current) 16%
  3. Return-related Queries (Previous) 23%
  4. Additional Inventory (Exclusive Deals) ₹16 Cr
  5. Average Order Frequency (Membership) 9 times/year
  6. Average Order Frequency (Typical) 4.2 times/year
  7. ARPU (Last Year Annualized) ₹20,000
  8. Current Revenue (Contextual) ₹250 Cr

What they filed

Q1 FY27: revenue up 36.9%, net profit up 46.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue59 63 73 60 73 +22%71 +14%72 −1%82 +37%
EBITDA6 6 7 3 6 −5%2 −67%0 −97%5 +61%
Net profit5 4 4 3 5 −7%2 −61%1 −69%4 +46%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex Capex disclosed
    As of now, there are no major capex plans that we have decided for FY27. If anything changes, we will communicate that appropriately.
  • M&A IDS Denmed Acquisition · Pending regulatory

    Strengthen ecosystem, accelerate offline growth, help margin expansion (especially equipment/instruments), support consumables growth, leverage significant institutional sales.

    Expected to help margin expansion, especially in equipment and instruments.

    We are progressing well and are currently awaiting approval from the National Stock Exchange for the IDS Denmed transaction. We remain committed to opportunities that strengthen our ecosystem.

Guidance & targets

Inventory

  • Inventory Days Inventory · short-term, long term · High confidence 120–150 days (short term), below 100 days (long term)
    Our short-term hypothesis is that inventory days should stabilise around 120–150 days, and in the long term, we expect this to be below 100 days.

    — Dr. Vikas Aggarwal

Profitability

  • EBITDA Margins Profitability · over time · Medium confidence mid-teens
    We believe that over time, EBITDA margins should move back towards the mid-teens as these investments start generating returns.

    — Dr. Vikas Aggarwal

Revenue

  • Revenue Revenue · by FY27 · High confidence ₹500–600 crore
    In the FY24 conference call, you mentioned targeting ₹500–600 crore revenue in three years, i.e., by FY27. Are we still on track? A – Dr. Vikas Aggarwal: Yes, we are broadly on track with the directional targets.

    — Dr. Vikas Aggarwal

  • Revenue Revenue · by FY29 · Medium confidence ₹800–1,200 crore
    On the longer-term ₹800–1,200 crore range by FY29, directionally, yes, we are aligned, but again I would treat this as an aspiration with execution dependency, not as a formal guidance.

    — Dr. Vikas Aggarwal

  • Smileworks Lab Revenue Revenue · long term · Low confidence well beyond the ₹50 crore
    In the long term, I believe Smileworks can go well beyond the ₹50 crore number you mentioned. However, it is too early to give a precise timeline even for the next two years so I would not want to commit to a specific year today. It is possible, but not yet the right time to quantify it.

    — Dr. Vikas Aggarwal

Operations

  • Average Delivery Time Operations · all-India basis · High confidence below 48 hours
    On an all-India basis, my aspiration is to bring the average delivery time down to below 48 hours.

    — Dr. Vikas Aggarwal

  • Return-related Queries Operations · within a year · High confidence below 5%
    our internal goal is to bring it below 5% within a year.

    — Dr. Vikas Aggarwal

Capacity

  • Service Centres in Tier I cities Capacity · within the next two years · High confidence all Tier I cities of India
    Our plan is to have our own service centres in all Tier I cities of India within the next two years.

    — Dr. Vikas Aggarwal

Customer Metrics

  • ARPU Customer Metrics · over 4–5 years · Medium confidence ₹1–1.5 lakh range
    What steps are being taken to move ARPU towards the ₹1–1.5 lakh range over 4–5 years? ... This is one lever to increase ARPU while deepening engagement and loyalty.

    — Dr. Vikas Aggarwal

What to watch in Q3 FY26

Inventory Days Stabilization

Next quarter / long term
Current High, around 120-150 days (short term)
Target Stabilize within 120-150 days, moving towards below 100 days long term

Why it matters

Indicates efficiency of new inventory management and demand forecasting, impacting cash flow.

Our short-term hypothesis is that inventory days should stabilise around 120–150 days, and in the long term, we expect this to be below 100 days.

Risks & concerns

  • Slower Growth

    medium

    Deliberate choice for long-term foundation, not demand weakness, but impacts short-term performance.

    Management acknowledged

  • EBITDA Margin Compression

    medium

    Short-term impact from investments in warehouses, tech, and new categories.

    Management acknowledged

  • Higher Inventory Levels

    medium

    Strategic decision for availability and trust, especially for new products, but leads to short-term inefficiency.

    Management acknowledged

  • Delivery Timelines

    medium

    Still a challenge compared to local distributors, requiring more warehouses and logistics investments.

    Management acknowledged

  • Transition Phase Duration

    medium

    The current investment and stabilization phase is expected to take longer than two quarters.

    Management acknowledged

Q&A highlights

8 direct
Slower Growth Rationale Direct
The slower growth is not due to any weakening of demand, loss of market position, or competitive pressure. It is a result of deliberate choices we have made internally over the last 12 months.

Management directly addresses a key investor concern about growth deceleration, attributing it to strategic internal investments rather than market issues.

Higher Inventory Rationale Direct
The simple truth is that in dentistry, especially in a fragmented B2B market like India, you cannot build trust without availability.

Explains the strategic reason behind increased inventory, linking it to customer trust and new product launches, rather than poor sales.

EBITDA Margin Compression Direct
New warehouses are taking time to stabilise and consume effort and opex. New categories, technology upgrades, hiring, and experimentation come with short-term cost pressure.

Clarifies that margin compression is a short-term consequence of strategic investments aimed at long-term operating leverage.

IDS Denmed Acquisition Strategy Direct
We believe that, over the long term, our own brands can also be distributed through them. Even after 10 years, some part of the market will definitely remain offline... IDS Denmed can be a very important lever to accelerate that growth.

Details the multi-faceted strategic benefits of the IDS Denmed acquisition, including offline presence, brand distribution, margin expansion, and institutional sales.

Asked by Mr. Shashank Agarwal

Equipment Mix vs. Consumables Growth Direct
We did not have a specific target to increase the percentage of equipment beyond consumables. It has gone up because, in the last 12 months, we focused a bit more on equipment. This is a short-term pattern, not a structural shift. Our long-term priority remains consumables.

Addresses concerns about changing product mix, clarifying that the recent shift towards equipment is a temporary focus, with consumables remaining the long-term priority.

Asked by Mr. Swaraj Mehta

Duration of Transition Phase Direct
I do not believe this will be over in just two quarters. It may take longer... it is hard to pin this down as a “two-quarter” vs “four-quarter" transition.

Provides a realistic timeline for the current investment and stabilization phase, managing investor expectations that it might extend beyond a couple of quarters.

Asked by Mr. Prolin Nandu

ARPU Expansion Strategy Direct
We have launched a membership program on Dentalkart. Early data shows: Membership customers order around 9 times a year, versus 4.2 times for a typical customer.

Highlights a concrete initiative (membership program) and its early positive impact on customer engagement and frequency, which is a key lever for ARPU growth.

Asked by Mr. Nikhil Porwal

Returns and Refund Policies Direct
Now, our philosophy is the opposite: We must trust the customer more if we want the customer to trust us... our internal goal is to bring it below 5% within a year.

Acknowledges a past customer concern and outlines a significant policy shift towards customer-centricity, aiming to improve trust and ARPU, despite potential short-term costs.

Asked by Mr. Nikhil Porwal

2 min read 6 chapters

Detailed narrative

Strategic Shift for Long-Term Foundation

Management emphasized a deliberate slowdown in growth over the past 12 months, attributing it to strategic internal choices rather than market weakness. This period was used to build a stronger foundation for the next decade, involving expansion of the warehouse network, increasing inventory to 20,000 SKUs, introducing new products, and upgrading technology platforms. These investments, while temporarily impacting growth and compressing EBITDA margins, are expected to stabilize and generate long-term operating leverage, with EBITDA margins targeted to return to mid-teens over time.

Inventory Management and Customer Trust

The company's decision to maintain higher inventory levels, including ₹16 crore of additional inventory for exclusive deals, is strategic. This ensures product availability, which is crucial for building trust in India's fragmented dental B2B market and supports new product launches. While inventory days are currently higher, they are expected to stabilize at 120-150 days in the short term, with a long-term goal of below 100 days, driven by improved data, machine learning, and forecasting.

IDS Denmed Acquisition and Offline Strategy

The acquisition of IDS Denmed is progressing, awaiting National Stock Exchange approval. This move is strategic for accelerating offline growth, distributing Vasa Denticity's own brands, and expanding institutional sales. IDS Denmed, with its deep offline presence and 2,000 dealers, is expected to enhance margin expansion, particularly in equipment and instruments, and indirectly support consumables growth, positioning Dentalkart as a dominant dental ecosystem.

ARPU Expansion and Customer Experience Initiatives

To drive Average Revenue Per User (ARPU) towards ₹1-1.5 lakh over 4-5 years, the company launched a membership program. Early data shows membership customers order 9 times a year, significantly higher than the 4.2 times for typical customers. Furthermore, the company is revamping its returns and refund policies to be more customer-friendly, aiming to reduce return-related queries from the current 16% of tickets to below 5% within a year, thereby building long-term trust and loyalty.

Technology, Logistics, and Service Infrastructure Investments

Significant investments have been made in technology, including a revamped app and website, capable of handling 3x the current order volume. In logistics, the company aims to reduce the average delivery time to below 48 hours across India, acknowledging that this is currently a challenge (~4 days). This will require more warehouses and potentially more expensive logistics. The plan also includes establishing service centers in all Tier I cities within the next two years to improve after-sales service for high-value equipment.

Long-Term Vision and Growth Targets

Vasa Denticity's long-term objective is to build a dominant dental ecosystem in India. The company is broadly on track for revenue targets of ₹500-600 crore by FY27 and an aspirational ₹800-1,200 crore by FY29. Smileworks Lab is on the path to break-even and is expected to grow well beyond ₹50 crore in the long term, though a precise timeline for this is not yet available. The focus remains on balancing speed and stability to scale 5x to 10x from current levels.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls